New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year
Eli Lilly's Omvoh (mirikizumab-mrkz) showed positive results in treating ulcerative colitis and Crohn's disease. In the LUCENT-2 study, 27.7% of UC patients achieved comprehensive disease control, while in VIVID-1, 20.4% of Crohn's patients achieved corticosteroid-free deep remission. Benefits were also seen in patients with prior biologic failure. The data will be presented at UEG Week 2026.
How this was made
The 30-second read
Why it matters
The results show statistically significant improvements versus placebo, which could influence analyst ratings and stock price.
Market read
First public disclosure of efficacy data; may affect LLY valuation and sector peers.
What to watch
Reimbursement and competition from other IL‑23 inhibitors could limit upside.
Background
Press release from Eli Lilly announcing new composite outcomes data for its drug Omvoh (mirikizumab‑mrkz) in ulcerative colitis and Crohn's disease.
Ticker impact
Lilly's Omvoh achieved 27.7% comprehensive disease control in ulcerative colitis versus 14% with placebo, a new clinical‑trial result.
potential upside as market prices in higher efficacy expectations
First disclosure of statistically significant efficacy over placebo; analysts often react positively to such data.
Market effects
May boost the broader IBD‑therapy and IL‑23 inhibitor sector.
US biotech stocks could see modest gains.
Limited to pharma/biotech investors.
Counterpoint
Data may not translate into commercial success if safety concerns emerge.
Key entities
- companyEli Lilly and Company
Pharmaceutical company reporting the trial data.
- drugOmvoh (mirikizumab‑mrkz)
IL‑23p19 inhibitor under investigation for IBD.
